Intrathecal Vector Delivery in Juvenile Rats via Lumbar Cistern Injection
Summary
A surgical procedure is described to perform injections into the lumbar cistern of the juvenile rat. This approach has been used for the intrathecal delivery of gene therapy vectors, but it is anticipated that this approach can be used for a variety of therapeutics, including cells and drugs.
Abstract
Gene therapy is a powerful technology to deliver new genes to a patient for the treatment of disease, be it to introduce a functional gene, inactivate a toxic gene, or provide a gene whose product can modulate the biology of the disease. The delivery method for the therapeutic vector can take many forms, ranging from intravenous infusion for systemic delivery to direct injection into the target tissue. For neurodegenerative disorders, it is often desirable to skew transduction towards the brain and/or spinal cord. The least invasive approach to target the entire central nervous system involves injection into the cerebrospinal fluid (CSF), allowing the therapeutic to reach a large fraction of the central nervous system. The safest approach to deliver a vector into the CSF is the lumbar intrathecal injection, where a needle is introduced into the lumbar cistern of the spinal cord. This technique, also known as a lumbar puncture, has been widely used in neonatal and adult rodents and in large animal models. While the technique is similar across species and developmental stages, subtle differences in size, structure, and elasticity of tissues surrounding the intrathecal space require accommodations in the approach. This article describes a method for performing lumbar puncture in juvenile rats to deliver an adeno-associated serotype 9 vector. Here, 25-35 µL of vector were injected into the lumbar cistern, and a green fluorescent protein (GFP) reporter was used to evaluate the transduction profile resulting from each injection. The benefits and challenges of this approach are discussed.
Introduction
The promise of viral-mediated gene therapies has finally been realized in recent years with the FDA approval of treatments for spinal muscular atrophy, retinal dystrophy, factor IX hemophilia, cancer, and more1,2,3,4. Countless other therapeutics are currently in development. Gene therapy aims to deliver a therapeutic gene to a patient's cells. The products of this new gene can replace the missing activity from a deficient endogenous gene, inhibit a toxic gene, kill cancerous cells, or provide some other beneficial function.
For diseases affecting the central nervous system (CNS), delivering the gene therapy vector directly to the target tissue is often desirable. Non-systemic approaches provide two benefits: they minimize off-target side effects that may be caused by peripheral transduction, and they greatly reduce the amount of vector needed to achieve adequate levels of transduction in the target tissue5.
There are a variety of approaches to delivering gene therapy vectors to the CNS. Intraparenchymal injection, the injection of a vector directly into the spinal cord or brain tissue, can be used for delivery to a defined region. However, for many diseases, broad transduction of the CNS is desired. This can be accomplished by delivering a vector to the cerebrospinal fluid (CSF)5, the fluid that flows in and around the brain and spinal cord. There are three primary ways to deliver vectors to the CSF. The most invasive approach is intracerebroventricular delivery, which involves drilling a burr hole through the skull and advancing a needle through the brain into the lateral ventricles. This yields transduction throughout the brain. However, the procedure may cause intracranial hemorrhage, and the approach generally produces only limited transduction of the spinal cord6. Injection into the cisterna magna at the base of the skull is less invasive, but carries the risk of damage to the brainstem. While often used in animal research5, injection into the cisterna magna is no longer used routinely in the clinic7. Lumbar puncture is the least invasive approach to access the CSF. This involves placing a needle between two lumbar vertebrae and into the lumbar cistern.
Lumbar puncture for vector delivery is routinely performed in adult rats and mice and in neonatal mice8,9. The authors of this study recently performed lumbar punctures in juvenile rats (28-30 days of age) to deliver adeno-associated virus serotype 9 (AAV9) vectors. In adult rats, a neonatal lumbar puncture needle was placed vertically between the L3 and L4 vertebrae9. Proper placement results in a tail flick and CSF flowing up into the needle reservoir. In juvenile rats, though, neither of these read-outs could be achieved. The authors then attempted to adapt an adult mouse procedure using a 27 G insulin syringe inserted at an angle between L5 and L610. In adult mice, which are typically smaller than P28 rats, this does not produce a tail flick, but incorrect needle placement is evident by the backflow of the injectate. In juvenile rats, however, this approach uniformly led to the injectate being delivered epidurally, likely resulting from different elasticity between adult mice and juvenile rats of the tissue layers surrounding the spinal cord. Catheter approaches were evaluated next. Specifically, a catheter was introduced through an incision in the dura of the lumbar cistern and up to the mid-thoracic spinal cord; however, this approach led to substantial reflux of the injectate back out of the incision site during delivery. Attempts to place the catheter into the intrathecal space percutaneously using a guide needle were also unsuccessful. Due to the narrowness of the interlaminar width, the catheter would likely hit the rostral lamina and fail to advance.
Here, a method is described to achieve successful and reproducible solution delivery via a lumbar puncture in the juvenile rat. This approach can be used for viral vectors, and likely also for cells, pharmaceuticals, and other therapeutics.
Protocol
This study was approved by the Emory University Institutional Animal Care and Use Committee (IACUC). Sprague-Dawley rats (28-30 days of age, mass in the range of about 90-135 g, males and females) were used in the present study.
1. Preparation of the vector
- Thaw the AAV9 vector (see Table of Materials) on ice at the beginning of the procedure.
- Centrifuge the microcentrifuge tube containing the vector briefly in a table-top centrifuge to ensure that all of the liquid is in the bottom of the tube.
- Gently flick the microcentrifuge tube to ensure that the solution is well-mixed.
2. Preparation of the recovery cage
- Place a clean cage onto an electric blanket (see Table of Materials) so that only half of the cage is in contact with the blanket.
- Set the temperature of the blanket to ~37 °C.
3. Preparation of the surgical platform
- Warm an isothermal pad (see Table of Materials) to 39 °C in a microwave or a water bath so that the contents become liquid.
- Place the isothermal pad on the surgical platform and cover it with a clean absorbent bench pad.
4. Animal preparation
- Anesthetize the rats with isoflurane in a clear box (following institutionally approved protocols). Begin the anesthesia induction using 5% isoflurane, and step down 1% per minute until reaching 2%. Hold the animal at 2% for an additional 3 min.
- Move the box holding the animal to a fume hood and open the box.
NOTE: This limits the surgeon's exposure to the anesthetic. - Remove the hair from the back of the animal using electric hair clippers.
NOTE: Alternatively, a depilatory cream or manual razor and shaving cream can be used. - Place the animal on the surgical platform with its snout in the anesthesia nose cone.
NOTE: The animal may begin to regain consciousness while the fur is removed from the surgical site. If this happens, anesthetize it again as described above. - Apply lubricating eye ointment to each eye to prevent drying of the corneas during the procedure.
- Disinfect the surgical area using three alternating applications of povidone-iodine and isopropanol wipes.
- Inject the analgesic(s) subcutaneously.
NOTE: Buprenorphine is generally used at a dose of 0.01-0.05 mg/kg, given every 12 h. Alternatively, a slow-release form of this drug can be given once at 1 mg/kg to provide adequate pain control for 72 h. Consult with the institution's IACUC for their guidelines regarding pain management. - Inject 100 µL of 1% lidocaine subcutaneously above the L2 to L6 spinous processes to provide local anesthesia.
- Place a roll of paper towel or a tube of 1.5 cm in diameter under the animal, just rostral to the hips. This helps flex the spine, making it easier to insert the needle between the two laminae.
- Place a fenestrated drape (see Table of Materials) on the animal, centering the fenestration over the lumbar spine.
5. Exposing the lumbar spine
- Confirm the depth of anesthesia by pinching each of the animal's paws and looking for the absence of a withdrawal response.
- Using a #11 scalpel blade, create an incision of approximately 3 cm long in the skin down the midline from L2 to L6.
- Loosen the skin from the muscle by inserting a sterile curved pair of surgical scissors between the muscle and the skin and then opening the tips.
- Remove the fascia covering the L2-L5 spinous processes.
6. Loading of the syringe
- Pipette 25-35 µL of the vector (to achieve the desired dose) into the cap of a sterile microcentrifuge tube.
- Draw the entire volume into the insulin syringe.
NOTE: Take care not to draw up air during this process.
7. Performing the injection
- Identify the L5 and L4 spinous processes.
NOTE: L6 sits directly between the two iliac crests, and its spinous process should be easy to identify by probing with a blunt instrument. The instrument can then be gently run up the back to find the boundaries of the L5 and L4 processes. - Place one hand so that the thumb rests gently on the animal's tail and one leg. Use a finger to steady the syringe.
- Position the needle of the syringe so that it is to the left of the L5 spinous process and lined up with its caudal end. Position the syringe so that it is about 30° off midline and 30° up from the plane of the table.
NOTE: It may be helpful to use a surgical microscope to better identify landmarks and position the tip of the needle. - Advance the syringe needle forward about 8 mm, over the top of the L5 lamina and then under the L4 lamina into the lumbar cistern until the bone is hit. Correct placement will result in a twitch of the leg and/or tail that can be seen or felt by the thumb resting on the leg/tail. If there is no twitch, remove the needle and attempt the procedure from the left side. If there is still no twitch, repeat the procedure between L4/L3 and L3/L2 as necessary.
- Depress the plunger slowly for about 5 s.
NOTE: There may be a twitch in the leg or tail during the injection. - Hold the syringe in place for about 30 s after fully depressing the plunger to allow the pressure to equilibrate and minimize reflux of the injectate when the needle is withdrawn.
- Slowly remove the needle.
8. Closing of the incision
- Approximate the edges of the incision.
- Beginning at one end of the wound, use a 4-0 suture (see Table of Materials) or surgical staples to close the incision.
9. Recovery and monitoring
- Place the animal in the prewarmed cage.
- Check the animal at least every 15 min until it is fully ambulatory.
NOTE: This should take between 15 min and 45 min. - For the next three days, perform wellness checks at least daily. Provide analgesics for the first 2 days following surgery or as required by the IACUC.
- One week after surgery, remove the sutures or staples.
10. Follow-up procedure
NOTE: To determine the accuracy of the injection technique, inject trypan blue dye as described above and then immediately euthanize the animal (following institutionally approved protocols) and perform a laminectomy to visualize the result.
- While the animal remains under anesthesia, euthanize it by administering a lethal dose of pentobarbital via intraperitoneal injection at a dose of 150 mg/kg.
- Once respiration and cardiac activity cease, open the chest cavity to ensure death. Extend the surgical incision up the back to the neck.
- Make an incision 4 cm long into the muscle parallel to the spine on both sides of the spinous processes, keeping as close as possible to the processes.
- Using fine forceps or scissors, remove the muscle from in between the spinous processes.
- Remove the spinous processes from L6 up to the lower-thoracic spine using a rongeur (see Table of Materials). Avoid twisting motions, as this may damage the rongeurs.
- Insert the lower tip of the rongeur under the L5 lamina and remove the bone overlying the spinal cord by taking several "bites" out of it.
NOTE: Pulling back on the L6 spinous process can make it easier to insert the tip of the rongeur. Care must be taken to prevent damage to the spinal cord. - Continue expanding the laminectomy at least four laminae rostrally. Inspect the interior surface of the laminae for signs of dye, which can indicate a failed injection.
Representative Results
To determine the accuracy of the injection technique, a dye, trypan blue, was used as a surrogate for the therapeutic. This dye readily binds to proteins, so it generally stays within the structure into which it was injected. This means the dye may not accurately predict the post-injection distribution of the therapeutic; it is simply used to reveal the accuracy of the injection. When successfully introduced into the lumbar cistern, trypan blue binds to the dura mater, staining the perimeter of the spinal cord blue. However, when the needle fails to penetrate the dura mater, the dye ends up in the epidural space. Both the dura mater and the surrounding tissues (the surface of the bone and the ligaments and muscles connecting the laminae) will be stained blue. These patterns are easily visible to the naked eye.
The difference between correctly and incorrectly administered injection is difficult to assess if one simply makes a transverse cut through the spinal cord and spinal column. Instead, performing a laminectomy using a pair of rongeurs beginning at the L5 lamina and moving rostrally is recommended. Care must be taken not to damage the dura mater in the process. Using the dissecting microscope makes this process easier. Figure 1 provides comparative examples of successful injections and only partially successful injections. With a successful injection, little to no reflux along the needle track is observed when the needle is withdrawn. Following a successful injection, removal of the lamina to expose the spinal cord reveals trypan blue within the spinal cord but not on the surface of the bone (Figure 1A). The dye is also visible on the brainstem and cerebellum following a successful injection (Figure 1B). In contrast, a partially successful injection is evidenced by significant reflux of dye back up the needle tract during the injection process and/or visible evidence of dye on the bone (Figure 1C).
Using the above procedure, 28 µL of an AAV9 vector expressing enhanced green fluorescent protein (GFP) was injected at a concentration of 3 x 1013 vector genomes/mL, for a total dose of 8.4 x 1011 vector genomes/animal. Four weeks later, the animals were euthanized and perfused with 4% paraformaldehyde10. The brain and spinal cord were then harvested and prepared for frozen sectioning. 40 µm thick sections were obtained and stained for GFP. Figure 2 provides examples of the transduction pattern obtained with this vector. The transduction was generally highest in the spinal cord, particularly in the lumbar region (Figure 2A–C), likely due to its proximity to the injection site. The transduction of the brain was achieved (Figure 2D–F), but, as expected, it tended to be more limited than what was seen in the spinal cord.
To illustrate the reproducibility of results achieved by a single, experienced surgeon using a single lot of virus, stained sections of the cerebellum and cortex from each of the 15 rats injected for this study are presented in Figure 3 and Figure 4, respectively. The stained sections of the cervical spinal cord are also presented for 7 of these 15 rats (Figure 5). Of course, the amount of brain transduction may show even greater variability with different doses, vector lots, and surgeons10.
Figure 1: Exposure of the spinal cord following an injection of the dye. Laminectomies were performed following the injection of trypan blue. (A) The spinal cord is stained blue in a correctly administered injection, and no dye is seen on the bone removed during the laminectomy (arrows). (B) The dye can also be observed around the brainstem. (C) In an injection where there was significant reflux during the injection, there is less dye within the cord, and dye is present on the surface of the bone (arrows). Please click here to view a larger version of this figure.
Figure 2: Examples of transduction patterns achieved following intrathecal delivery of AAV9-GFP. 40 µm thick sections of (A) cervical, (B) thoracic, and (C) lumbar spinal cord were immunohistochemically stained for GFP (black stain). High levels of gray matter transduction were observed at all levels. (D) In contrast, the brain exhibits sparser overall transduction. The left and right boxes are magnified in (E) and (F), respectively. (E) The majority of the staining is observed in the cerebellum, primarily in Purkinje neurons (arrows). (F) Neurons (arrows) and astrocytes (arrowheads) are transduced within the cerebral cortex. Scale bars: (A–C) 325 µm; (D) 5 mm; and (E,F) 200 µm. Please click here to view a larger version of this figure.
Figure 3: Reproducibility of transduction in the cerebellum. Reproducibility of transduction in the cerebellum of 15 rats injected by the same surgeon using the same dose and lot of the virus. Scale bar: 1 mm. The numbers in the images indicate the rat ID numbers ('litter'.'individual'). Please click here to view a larger version of this figure.
Figure 4: Reproducibility of transduction in the cortex. Reproducibility of transduction in the cortex of 15 rats injected by the same surgeon using the same dose and lot of virus. Scale bar: 500 µm. The numbers in the images indicate the rat ID numbers ('litter'.'individual'). Please click here to view a larger version of this figure.
Figure 5: Reproducibility of transduction in the cervical spinal cord. Reproducibility of transduction in the cervical spinal cord of 7 rats injected by the same surgeon using the same dose and lot of virus. Scale bar: 500 µm. The numbers in the images indicate the rat ID numbers ('litter'.'individual'). Please click here to view a larger version of this figure.
Discussion
A wide variety of diseases affect the CNS. Providing a functional copy of the relevant gene via a viral vector is an attractive treatment strategy for those that are recessive and monogenic in nature, such as spinal muscular atrophy. However, the blood-brain barrier (BBB) excludes most gene therapy vectors given intravenously11. Those that can cross the BBB, such as AAV9, must be given in high doses to overcome the vector loss due to peripheral transduction12. The age is also a barrier. Environmental exposure to the various AAV serotypes increases with age13 and often leads to the production of antibodies that can neutralize therapeutic vectors14. Therefore, intravenous delivery of gene therapy vectors for CNS disorders is generally limited to infants and is not used in patients diagnosed later in life.
For older patients, direct vector injection into the CSF can yield broad transduction in the CNS, bypassing both the BBB and preexisting anti-AAV antibodies15. Since this approach is targeted, lower vector doses can also be used. There are two primary approaches in the clinical setting: (1) lumbar puncture and (2) injection into the lateral ventricles. The latter carries more risk, but generally provides greater brain transduction. Lumbar puncture is safer, but transduction is skewed towards the spinal cord. Brain transduction might be enhanced by placing the patient into the Trendelenburg position, but data on this are mixed16,17. The use of a catheter to reach the cisterna magna via a lumbar puncture may provide a better option in the clinic, but it is in an early stage of use5. There may be other challenges to translating approaches worked out in animal models to the clinic, such as vector loss due to CSF leakage18 and toxicity in the dorsal root ganglia19.
Most studies of CNS-directed therapies performed in rodents use neonates or adult animals (>60 days of age). Neonates have the benefit of a small body size, allowing for higher effective doses, and an immature immune system, avoiding the complications of an immune response against the therapeutic. However, in terms of brain development, a newborn mouse or rat better represents a fetal stage in humans. For therapies intended for children in the 5-10 year age range, the juvenile rat (25-35 days old) is a better model in terms of neurological development20. Since a method for intrathecal injection had not been previously described for juvenile rats, and methods established for adult mice and rats proved to be ineffective in rats at this age, the approach described above was developed. To be clear, juvenile rats are not only smaller than adults but may also differ in the elasticity of the dura that protects the spinal cord, making a procedure that works to puncture this layer in an adult rat ineffective in a juvenile.
When learning how to perform intrathecal injection in juvenile rats, using a dye (such as trypan blue) as a surrogate for the therapeutic is necessary, and the user should be highly confident in their ability to successfully and reproducibly perform the procedure prior to starting a study with a therapeutic. Becoming proficient in the technique will require practice to get experience with how the syringe feels when the trajectory is on-target versus off-target. There are two common errors. If the angle of approach is too shallow, the needle will strike the top of one of the laminae or the back of the rostral lamina. There will be no twitch, and the distance that the needle advances will be a few millimeters short of 8 mm. If the angle of approach is too great, there is a risk that the needle will pass between the two laminae and penetrate the abdominal cavity. When this happens, the needle will advance much farther than 8 mm. If this happens, remove the needle, reposition, and try again. On the few occasions that this has happened, transiently entering the abdominal cavity by a few millimeters before withdrawal and repositioning has not caused any apparent lasting harm to the animals.
It has been found that observing a physical response to the placement of the needle is critical to achieving reproducibility with a high rate of success with this procedure. When there was no response, the success rate for the injection was low. However, in some cases, an animal required attempts at multiple sites to achieve a response, and trace amounts of dye were observed in one or more of the previous needle tracks. No dye was observed in the epidural space, suggesting that some of the previous needle sticks had penetrated the dura without producing a tail or leg twitch. Since the reflux was minimal (similar to what is observed in the needle track from the injection), it is thought that the effect of previous needle sticks on delivery efficacy in these instances was negligible.
Once one achieves proficiency in the delivery technique, a second, non-surgical challenge may be encountered. Specifically, in adult rats (~70 days of age), the potency of AAV9 vectors for intrathecal delivery to the spinal cord and brain can vary substantially from lot to lot, even when they are generated by the same vector core. Some batches will perform as expected, yielding transduction in the spinal cord gray matter along its length. Others, though, will fail to penetrate the gray matter, primarily transducing dorsal root ganglia10. The cause for this variability is unclear, as the vectors are potent in vitro and when injected directly into the spinal cord. It is recommended that a pilot study of 3-4 animals be performed with any new batch of virus to confirm that the new lot performs as expected before beginning a large study. Potency can be assessed using either immunohistochemical or immunofluorescence staining of the protein transgene product or quantifying the amount of transgene mRNA or vector genomes using quantitative PCR or ddPCR21. In addition to the unknown variables that distinguish viral lots, small differences in animal age, injection volume, speed of delivery, and vector concentration may cause variability in results. Before beginning a large study, they may need to be optimized for each virus or other candidate therapeutic agent.
Once trained, an experienced surgeon can complete the intrathecal injection procedure of a juvenile rat within about 30 min, from anesthesia induction to the beginning of the recovery period. This allows for large cohorts to be treated in a short amount of time. Recovery from the surgery is also rapid. Most animals ambulate normally within 20-30 min. After performing more than 200 of these surgeries, no adverse effects from this procedure have been encountered.
Finally, minimizing animal distress and ensuring animal welfare during surgical procedures are paramount considerations. Thus, the proper use of anesthetics and analgesics is required, and body temperature must be maintained during the procedure and until the animal fully recovers from anesthesia. The relevant regulatory bodies and veterinary staff at different institutions may have different requirements and recommendations regarding these topics. The use of anesthetics and analgesics described in this procedure was developed in consultation with the Emory University veterinarians and IACUC staff. Researchers should work closely with their local veterinarians and IACUC to meet the needed goals.
There are certain limitations to this procedure. The method described here was developed for use in juvenile rats, and myriad structural and other differences between humans and rats may limit the translation of these procedures to humans. The point of enabling lumbar intrathecal injection of a therapeutic in juvenile rats is to facilitate the use of the juvenile rat model for testing the efficacy of the candidate therapeutic treatment – even if the precise mode of delivery would need to be altered for application in patients.
Disclosures
The authors have nothing to disclose.
Acknowledgements
The authors would like to thank Steven Gray, Matthew Rioux, Nanda Regmi, and Lacey Stearman of UT Southwestern for a productive discussion of the challenge posed by juvenile rats for intrathecal injection. This work was partly supported by funding from Jaguar Gene Therapy (to JLFK).
Materials
| 200 µL filtered pipette tips | MidSci | PR-200RK-FL | Pipetting virus |
| AAV9-GFP | Vector Builder | P200624-1005ynr | AAV9 vector expressing GFP |
| Absorbable Suture with Needle Coated Vicryl Polyglactin 910 FS-2 3/8 Circle Reverse Cutting Needle Size 4 – 0 Braided | McKesson | J422H | Suture |
| Bench pad | VWR | 56616-031 | Surgery |
| Braintree Scientific Isothermal Pads, 8'' x 8'' | Fisher Scientific | 50-195-4664 | Maintains body temperature |
| Buprenorphine | McKesson | 1013922 | Analgesic |
| Buprenorphine-ER (1 mg/mL) | Zoopharma | Extended-release analgesic | |
| Cotton swabs | Fisher Scientific | 19-365-409 | Blood removal |
| Drape, Mouse, Clear Plastic, 12" x 12", with Adhesive Fenestration | Steris | 1212CPSTF | Surgical drape |
| Dumont #5 Forceps | Fine Science Tools | 11251-20 | Forceps |
| Electric Blanket | CVS Health | CVS Health Series 500 Extra Long Heating Pad | |
| Eppendorf Research plus, 1-channel pipette, variable, 20–200 µL | Eppendorf | 3123000055 | Pipetting virus |
| Fine Scissors | Fine Science Tools | 14059-11 | Curved surgical scissors |
| Friedman-Pearson Rongeurs | Fine Science Tools | 16121-14 | Laminectomy |
| Halsey Needle Holders | Fine Science Tools | 12001-13 | Needle driver |
| Insulin Syringes with Ultra-Fine Needle 12.7 mm x 30 G 3/10 mL/cc | BD | 328431 | Syringe |
| Isoflurane | McKesson | 803250 | Anesthetic |
| Isopropanol wipes | Fisher Scientific | 22-031-350 | Skin disinfection |
| Lidocaine, 1% | McKesson | 239935 | Local anesthesia |
| Microcentrifuge Tubes: 1.5mL | Fisher Scientific | 05-408-137 | Loading the syringe |
| Povidone-iodine | Fisher Scientific | 50-118-0481 | Skin disinfection |
| Scalpel Handle – #4 | Fine Science Tools | 10004-13 | Scalpel blade holder |
| Sure-Seal Induction Chamber | Braintree Scientific | EZ-17 | Anesthesia box |
| Surgical Blade Miltex Carbon Steel No. 11 Sterile Disposable Individually Wrapped | McKesson | 4-111 | #11 Scalpel blade |
| SYSTANE NIGHTTIME Eye Ointment | Alcon | Eye ointment | |
| Trypan Blue | VWR | 97063-702 | Injection |
References
- Wurster, C., Petri, S. Progress in spinal muscular atrophy research. Curr Opin Neurol. 35 (5), 693-698 (2022).
- Wu, K. Y., et al. Retinitis pigmentosa: Novel therapeutic targets and drug development. Pharmaceutics. 15 (2), 685 (2023).
- Larkin, H. First FDA-approved gene therapy for hemophilia. JAMA. 329 (1), 14 (2023).
- Lee, A. Nadofaragene firadenovec: First approval. Drugs. 83 (4), 353-357 (2023).
- Taghian, T., et al. A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna. Mol Ther. 28 (2), 411-421 (2020).
- Donsante, A., et al. Intracerebroventricular delivery of self-complementary adeno-associated virus serotype 9 to the adult rat brain. Gene Ther. 23 (5), 401-407 (2016).
- Pellot, J. E., Jesus, O. D. Suboccipital puncture. [Updated 2022 Jul 25]. StatPearls [Internet]. , (2022).
- Elliger, S. S., Elliger, C. A., Aguilar, C. P., Raju, N. R., Watson, G. L. Elimination of lysosomal storage in brains of MPS vii mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther. 6 (6), 1175-1178 (1999).
- De La Calle, J. L., Paino, C. L. A procedure for direct lumbar puncture in rats. Brain Res Bull. 59 (3), 245-250 (2002).
- O’connor, D. M., Lutomski, C., Jarrold, M. F., Boulis, N. M., Donsante, A. Lot-to-lot variation in adeno-associated virus serotype 9 (AAV9) preparations. Hum Gene Ther Methods. 30 (6), 214-225 (2019).
- Manfredsson, F. P., Rising, A. C., Mandel, R. J. AAV9: A potential blood-brain barrier buster. Mol Ther. 17 (3), 403-405 (2009).
- Hudry, E., Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: A clinical reality. Neuron. 101 (5), 839-862 (2019).
- Georg-Fries, B., Biederlack, S., Wolf, J., Zur Hausen, H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology. 134 (1), 64-71 (1984).
- Schulz, M., et al. Binding and neutralizing anti-aav antibodies: Detection and implications for rAAV-mediated gene therapy. Mol Ther. 31 (3), 616-630 (2023).
- Gray, S. J., Nagabhushan Kalburgi, S., Mccown, T. J., Samulski, J. R. Global CNS gene delivery and evasion of anti-aav-neutralizing antibodies by intrathecal aav administration in non-human primates. Gene Ther. 20 (4), 450-459 (2013).
- Meyer, K., et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for sma: A dose-response study in mice and non-human primates. Mol Ther. 23 (3), 477-487 (2015).
- Hinderer, C., et al. Evaluation of intrathecal routes of administration for adeno-associated viral vectors in large animals. Hum Gene Ther. 29 (1), 15-24 (2018).
- Wang, Y. F., et al. Cerebrospinal fluid leakage and headache after lumbar puncture: A prospective non-invasive imaging study. Brain. 138, 1492-1498 (2015).
- Hordeaux, J., et al. Adeno-associated virus-induced dorsal root ganglion pathology). Hum Gene Ther. 31 (15-16), 808-818 (2020).
- Semple, B. D., Blomgren, K., Gimlin, K., Ferriero, D. M., Noble-Haeusslein, L. J. Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Prog Neurobiol. 106-107, 1-16 (2013).
- Fang, H., et al. Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer. Hum Gene Ther Methods. 23 (4), 234-241 (2012).
